Every 10-Q that TransMedics Group, Inc. (TMDX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TMDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMDX filings page.
TransMedics Group, Inc. reported net revenue of $173.9 million for the quarter ended March 31, 2026, up from $143.5 million a year earlier, driven mainly by strong U.S. liver transplant activity. U.S. OCS liver revenue rose to $139.0 million from $108.7 million, while heart and lung revenue were roughly flat to down slightly.
Gross profit increased to $101.2 million, but higher research and development and selling, general and administrative expenses reduced income from operations to $13.3 million from $27.4 million. Net income declined to $7.3 million (diluted EPS $0.20) from $25.7 million (diluted EPS $0.70).
The company ended the quarter with $480.2 million in cash and restricted cash and total assets of $1.43 billion, reflecting recognition of a large $334.5 million finance lease right-of-use asset for its new Somerville, Massachusetts headquarters. Operating cash flow improved to $24.5 million, while capital expenditures were $36.7 million.
TransMedics Group (TMDX) reported strong third-quarter results. Total revenue rose to $143.8 million, up from $108.8 million a year ago, with net income of $24.3 million versus $4.2 million last year. Gross profit reached $84.6 million, reflecting higher product and service activity across the Organ Care System (OCS) platform.
Growth was concentrated in the United States, where OCS transplant revenue totaled $139.0 million, led by liver at $107.9 million and heart at $27.4 million. Diluted EPS was $0.66 (basic $0.71). Year‑to‑date, revenue was $444.7 million with $84.9 million of net income and $158.3 million in cash from operations.
The balance sheet strengthened with $466.2 million in cash and $355.2 million in stockholders’ equity. The company reported $452.1 million net carrying value of its 1.50% convertible senior notes due 2028 and $54.6 million in long‑term bank debt. As of October 17, 2025, 34,174,325 common shares were outstanding.